PriceTargets.com logo

Sotera Health - SHC Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $16.08
  • Forecasted Upside: 21.48%
  • Number of Analysts: 7
  • Breakdown:
  • 0 Sell Ratings
  • 3 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$13.24 As of 12/20/2024 06:16 PM ET
▼ -0.03 (-0.23%)

This chart shows the closing price for SHC by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Sotera Health Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for SHC and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for SHC

Analyst Price Target is $16.08
▲ +21.48% Upside Potential
This price target is based on 7 analysts offering 12 month price targets for Sotera Health in the last 3 months. The average price target is $16.08, with a high forecast of $20.00 and a low forecast of $13.00. The average price target represents a 21.48% upside from the last price of $13.24.

This chart shows the closing price for SHC for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 7 contributing investment analysts is to moderate buy stock in Sotera Health. This rating has held steady since January 2024, when it changed from a Buy consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
6/29/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
9/27/2023
  • 0 strong buy ratings
  • 4 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
12/26/2023
  • 0 strong buy ratings
  • 3 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
3/25/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
6/23/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
9/21/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 2 hold ratings
  • 0 sell ratings
Ratings as of
11/20/2024
  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings
Ratings as of
12/20/2024

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 3 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
12/6/2024The Goldman Sachs GroupInitiated CoverageNeutral$14.00
11/21/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$17.00 ➝ $17.00
11/6/2024CitigroupBoost TargetBuy ➝ Buy$18.00 ➝ $20.00
8/6/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$17.00 ➝ $17.00
8/6/2024BarclaysBoost TargetOverweight ➝ Overweight$14.00 ➝ $17.00
5/21/2024Piper SandlerInitiated CoverageNeutral$13.00
4/10/2024BarclaysLower TargetOverweight ➝ Overweight$19.00 ➝ $14.00
4/3/2024CitigroupUpgradeNeutral ➝ Buy$18.00 ➝ $16.00
3/25/2024Jefferies Financial GroupUpgradeHold ➝ Buy$15.00 ➝ $15.50
3/4/2024Royal Bank of CanadaReiterated RatingOutperform ➝ Outperform$20.00
2/28/2024BarclaysBoost TargetOverweight ➝ Overweight$17.00 ➝ $19.00
2/6/2024KeyCorpInitiated CoverageSector Weight
1/25/2024BarclaysBoost TargetOverweight ➝ Overweight$15.00 ➝ $17.00
11/2/2023BarclaysLower TargetOverweight ➝ Overweight$20.00 ➝ $15.00
11/2/2023Royal Bank of CanadaLower TargetOutperform ➝ Outperform$22.00 ➝ $20.00
8/4/2023Royal Bank of CanadaBoost TargetOutperform ➝ Outperform$18.00 ➝ $22.00
8/4/2023KeyCorpLower TargetOverweight ➝ Overweight$24.00 ➝ $23.00
5/4/2023BarclaysLower Target$21.00 ➝ $20.00
4/4/2023BarclaysLower TargetOverweight$22.00 ➝ $21.00
3/1/2023Royal Bank of CanadaBoost TargetOutperform$8.00 ➝ $19.00
1/23/2023JPMorgan Chase & Co.UpgradeUnderweight ➝ Neutral$6.00 ➝ $18.00
1/10/2023Wolfe ResearchUpgradePeer Perform ➝ Outperform$25.00
1/10/2023BarclaysUpgradeUnderweight ➝ Overweight$6.00 ➝ $22.00
11/23/2022The Goldman Sachs GroupLower TargetNeutral$9.00 ➝ $8.00
11/15/2022BarclaysDowngradeEqual Weight ➝ Underweight$7.00 ➝ $6.00
11/3/2022JPMorgan Chase & Co.Lower TargetUnderweight$9.00 ➝ $6.00
11/3/2022Royal Bank of CanadaLower TargetOutperform$25.00 ➝ $8.00
10/6/2022BarclaysLower TargetEqual Weight$22.00 ➝ $8.00
10/5/2022CitigroupDowngradeBuy ➝ Neutral$25.00 ➝ $9.00
9/21/2022JPMorgan Chase & Co.DowngradeOverweight ➝ Underweight$26.00 ➝ $9.00
9/20/2022The Goldman Sachs GroupDowngradeBuy ➝ Neutral$23.00 ➝ $9.00
7/13/2022BarclaysLower TargetEqual Weight$24.00 ➝ $22.00
6/9/2022Wolfe ResearchDowngradeOutperform ➝ Peer Perform$26.00
4/5/2022Wolfe ResearchInitiated CoverageOutperform$26.00
3/21/2022The Goldman Sachs GroupLower TargetBuy$31.00 ➝ $27.00
3/3/2022Jefferies Financial GroupDowngradeBuy ➝ Hold$34.00 ➝ $22.00
3/2/2022Credit Suisse GroupLower TargetOutperform$31.00 ➝ $28.00
3/2/2022KeyCorpLower TargetOverweight$33.00 ➝ $30.00
3/2/2022BarclaysDowngradeOverweight ➝ Equal Weight$24.00
8/13/2021BarclaysBoost TargetOverweight$30.00 ➝ $32.00
7/13/2021BarclaysBoost TargetOverweight$29.00 ➝ $30.00
5/25/2021Credit Suisse GroupReiterated RatingBuy$31.00
5/14/2021BarclaysLower TargetOverweight$35.00 ➝ $29.00
3/10/2021KeyCorpBoost TargetOverweight$31.00 ➝ $33.00
3/2/2021BarclaysInitiated CoverageOverweight$35.00
1/13/2021Robert W. BairdInitiated CoverageOutperform$31.00
12/15/2020Smith Barney CitigroupInitiated CoverageBuy$32.00
12/15/2020KeyCorpInitiated CoverageOverweight$31.00
12/15/2020JPMorgan Chase & Co.Initiated CoverageOverweight$35.00
12/15/2020Jefferies Financial GroupInitiated CoverageBuy$33.50
12/15/2020Royal Bank of CanadaInitiated CoverageOutperform$31.00
12/15/2020Credit Suisse GroupInitiated CoverageOutperform$31.00
12/15/2020The Goldman Sachs GroupInitiated CoverageBuy$34.00
(Data available from 12/21/2019 forward)

News Sentiment Rating

1.00 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 3 very positive mentions
  • 16 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
5/25/2024
  • 7 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
6/24/2024
  • 3 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
7/24/2024
  • 3 very positive mentions
  • 15 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
8/23/2024
  • 8 very positive mentions
  • 6 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/22/2024
  • 12 very positive mentions
  • 3 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
10/22/2024
  • 7 very positive mentions
  • 18 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
11/21/2024
  • 16 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/21/2024

Current Sentiment

  • 16 very positive mentions
  • 10 positive mentions
  • 0 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

  • No negative mentions tracked during this time.

Positive

Very Positive

Sotera Health logo
Sotera Health Company engages in the provision of sterilization, lab testing, and advisory services in the United States and internationally. The company operates through three segments: Sterigenics, Nordion, and Nelson Labs. It provides mission-critical end-to-end sterilization services, including gamma and electron beam irradiation, and ethylene oxide processing, as well as designs, installs, and maintains gamma irradiation systems. The company also provides microbiological and analytical chemistry testing, as well as technical assistance, regulatory consulting, and advisory services. It serves medical devices, pharmaceuticals, food safety, agricultural products, cancer treatment, and high-performance materials industries, as well as commercial, advanced, and specialty application industries. The company was formerly known as Sotera Health Topco, Inc. and changed its name to Sotera Health Company in October 2020. Sotera Health Company was incorporated in 2015 and is headquartered in Broadview Heights, Ohio.
Read More

Today's Range

Now: $13.24
Low: $13.24
High: $13.66

50 Day Range

MA: $14.39
Low: $12.41
High: $16.11

52 Week Range

Now: $13.24
Low: $10.71
High: $17.44

Volume

3,232,129 shs

Average Volume

1,343,184 shs

Market Capitalization

$3.75 billion

P/E Ratio

52.96

Dividend Yield

N/A

Beta

1.96

Frequently Asked Questions

What sell-side analysts currently cover shares of Sotera Health?

The following Wall Street sell-side analysts have issued research reports on Sotera Health in the last twelve months: Barclays PLC, Citigroup Inc., Jefferies Financial Group Inc., KeyCorp, Piper Sandler, Royal Bank of Canada, The Goldman Sachs Group, Inc., and TheStreet.
View the latest analyst ratings for SHC.

What is the current price target for Sotera Health?

0 Wall Street analysts have set twelve-month price targets for Sotera Health in the last year. Their average twelve-month price target is $16.08, suggesting a possible upside of 21.5%. Citigroup Inc. has the highest price target set, predicting SHC will reach $20.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $13.00 for Sotera Health in the next year.
View the latest price targets for SHC.

What is the current consensus analyst rating for Sotera Health?

Sotera Health currently has 3 hold ratings and 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for SHC.

What other companies compete with Sotera Health?

Other companies that are similar to Sotera Health include Fresenius Medical Care, Hims & Hers Health, Guardant Health, Option Care Health and Veracyte. Learn More about companies similar to Sotera Health.

How do I contact Sotera Health's investor relations team?

Sotera Health's physical mailing address is 9100 SOUTH HILLS BLVD SUITE 300, BROADVIEW HEIGHTS OH, 44147. The company's listed phone number is 440-262-1410 and its investor relations email address is [email protected]. The official website for Sotera Health is www.soterahealth.com. Learn More about contacing Sotera Health investor relations.